Yun-Fan Liaw

TL;DR: Since the introduction of the hepatitis B vaccine and other preventive measures, the worldwide prevalence of hepatitis B infection has fallen, but chronic infection remains a challenging global health problem, with more than 350 million people chronically infected and at risk of liver injury and disease progression.

TL;DR: The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy.

TL;DR: It is suggested that spontaneous HBeAg seroconversion confers favorable long‐term outcomes, however, active hepatitis still may develop and lead to cirrhosis and HCC.

TL;DR: The results indicate that acute exacerbations may occur after emergence of the YMDD mutation, and possibly the underlying immune mechanisms, are similar to those of wild‐type HBV chronic infection.

TL;DR: There is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypesic, and clinical resistance to NA therapy.